IL22RA1 and breast carcinoma: To screen for lncRNAs that may potentially participate in the IL-22-IL-22R1 pathway during breast cancer progression, we treated MDA-MB-231 and MCF-7 cells with PBS (control) or IL-22, and detected expression changes of the top 20 upregulated lncRNAs in BC [15].